stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Book value per share
NewAmsterdam Pharma Company N.V.'s book value per share at the end of fiscal 2025 was 5.8×, down 28.1% from 8.0× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 5.1×. Over the past ten years it has ranged from −3.4× (fiscal 2020) to 22.7× (fiscal 2022); the current reading is higher than 56% of that period. NewAmsterdam Pharma Company N.V. ranks 154th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.8× | (28.11%) |
| FY2024 | 8.0× | 128.71% |
| FY2023 | 3.5× | (84.52%) |
| FY2022 | 22.7× | 257.65% |
| FY2022 | 6.3× | — |
| FY2021 | −1.8× | — |
| FY2021 | 2.3× | — |
| FY2020 | −3.4× | — |
| FY2020 | 7.2× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 5.1× | (0.72%) |
| Jun 2026 | 5.1× | (6.35%) |
| Mar 2026 | 5.5× | (5.30%) |
| Dec 2025 | 5.8× | (5.67%) |
| 21 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 9.2× |
| MBX MBX Biosciences, Inc. compare | 8.6× |
| XNCR Xencor, Inc. compare | 6.6× |
| PHVS Pharvaris N.V. compare | 5.1× |
| NAMS NewAmsterdam Pharma Company N.V. | 5.1× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 1.7× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Revenue growth
- Altman Z-score
- The full statement